Pharmacotherapy of actinic keratosis: an update
- 14 August 2012
- journal article
- review article
- Published by Taylor & Francis Ltd in Expert Opinion on Pharmacotherapy
- Vol. 13 (13), 1847-1871
- https://doi.org/10.1517/14656566.2012.716039
Abstract
Introduction: Actinic keratosis (AK) represents the initial intraepidermal manifestation of abnormal keratinocyte proliferation, with the potential of progression to squamous cell carcinoma (SCC). Few visible AKs lead to the use of lesion-directed treatments, including ablative and/or surgical procedures. Multiple and/or the suspicion of subclinical (non-visible) AKs lead to the use of field-directed therapies, including topical and ablative treatments. Predicting which AK will progress to SCC is difficult, and so all are treated. The goals of treatment are to eliminate visible AKs and to treat subclinical (non-visible) AKs, minimizing their risk of progression to invasive SCC, while pursuing good cosmesis. Areas covered: This review discusses the prevention of AKs (such as ultraviolet light avoidance, sunscreen use, protective clothing, and frequent self-examinations, in addition to chemoprevention with retinoids, eflornithine, silymarin, and others). It also covers lesion-directed treatments (e.g., cryotherapy, electrodessication and curettage, and surgery). Field-directed treatments are also mentioned (including laser resurfacing, dermabrasion, chemical peels, topical immunomodulators (imiquimod and diclofenac), topical chemotherapeutic agents (5-fluorouracil and retinoids), and photodynamic therapy). Finally, newer and investigational treatments are discussed (including ingenol mebutate). Expert opinion: There is no panacea in the treatment of AKs. The current best approach is the sequential treatment with a lesion-directed and a field-directed therapy. Several combinations seem to work well; they just need to be selected based on the evidence and adjusted to patient needs, preferences and dermatologist expertise.Keywords
This publication has 156 references indexed in Scilit:
- Prospects for Skin Cancer Treatment and Prevention: The Potential Contribution of an Engineered VirusJournal of Investigative Dermatology, 2011
- TAT-Mediated Delivery of a DNA Repair Enzyme to Skin Cells Rapidly Initiates Repair of UV-Induced DNA DamageJournal of Investigative Dermatology, 2011
- Imiquimod 5% cream for the treatment of actinic keratosis: Results from a phase III, randomized, double-blind, vehicle-controlled, clinical trial with histologyJournal of the American Academy of Dermatology, 2004
- Imiquimod 5% cream for the treatment of actinic keratosis: results from two phase III, randomized, double-blind, parallel group, vehicle-controlled trialsJournal of the American Academy of Dermatology, 2004
- Actinic damage and skin cancer in albinos in northern Tanzania: Findings in 164 patients enrolled in an outreach skin care programJournal of the American Academy of Dermatology, 1995
- Guidelines of care for actinic keratosesJournal of the American Academy of Dermatology, 1995
- Clinical evaluation of topical isotretinoin in the treatment of actinic keratosesJournal of the American Academy of Dermatology, 1994
- Reduction of Solar Keratoses by Regular Sunscreen UseNew England Journal of Medicine, 1993
- Weekly pulse dosing: Effective and comfortable topical 5-fluorouracil treatment of multiple facial actinic keratosesJournal of the American Academy of Dermatology, 1991
- Topical treatment of multiple actinic keratoses of the face with arotinoid methyl sulfone (Ro 14-9706) cream versus tretinoin cream: A double-blind, comparative studyJournal of the American Academy of Dermatology, 1991